Rigel Assumes Development Responsibility For Inhaled Asthma – BioResearch Online (press release)

Rigel Assumes Development Responsibility For Inhaled Asthma
BioResearch Online (press release)
South San Francisco, CA /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials.

View full post on asthma – Google News

Rigel Assumes Development Responsibility For Inhaled Asthma Therapy – Medical News Today (press release)

Rigel Assumes Development Responsibility For Inhaled Asthma Therapy
Medical News Today (press release)
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer Inc. is returning full rights to the

and more »

View full post on asthma – Google News

Rigel Assumes Development Responsibility for Inhaled Asthma Therapy – PR Newswire (press release)

Rigel Assumes Development Responsibility for Inhaled Asthma Therapy
PR Newswire (press release)
SOUTH SAN FRANCISCO, Calif., May 6, 2011 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1

and more »

View full post on asthma – Google News